April 25th 2024
A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.
iLet Bionic Pancreas Improves Glycemic Control, Time in Target Range in Type 1 Diabetes
September 28th 2022In data published in the New England Journal of Medicine, the iLet Bionic Pancreas was associated with improved glycemic control and time in target glucose range compared to standard care in a cohort of people with type 1 diabetes aged 6-79 years of age.
Diabetes Dialogue: September 2022
September 28th 2022In this regularly scheduled September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (AID) systems in clinical practice published in Endocrine Reviews, which Isaacs helped compose as a member of the writing committee.
AACE Releases New 2022 Diabetes Management Guidelines
September 27th 2022Announced on September 27, the latest guideline recommendations on diabetes management from the American Academy of Clinical Endocrinology represent their first update on the topic since 2015 and contains 170 new or updated evidence-based recommendations.
Endocrine Month in Review: September 2022
September 25th 2022Our endocrinology month in review spotlights the most popular content from the past month. Our top content from September 2022 includes new guideline recommendations from the ADA/EASD, new data on semaglutide 2.4 mg and tirzepatide, a label update for finerenone, & more!
Studies Debate Link Between COVID-19 and Increased Type 1 Diabetes Diagnoses
September 24th 2022A pair of studies published within days of one another provide insight into the apparent increase in risk of type 1 diabetes diagnoses following COVID-19, but one study purports this increase may not be the result of COVID-19.
GLP-1 RA, Insulin Glargine Outperform DPP-4 Inhibitors and Sulfonyulreas in GRADE Study
September 22nd 2022Results of the Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study provide insight into the comparative effectiveness of DPP-4 inhibitors, GLP-1 RAs, sulfonylureas, and insulin glargine for glycemic control and cardiovascular outcomes in people with type 2 diabetes.
Study Forecasts Number of People with Type 1 Diabetes to Double by 2040
September 21st 2022Results of a modeling study provide insight into the projected prevalence of type 1 diabetes in 2040 as well as offering an overview of the estimates of the current undiagnosed cases, current life expectancy differences based on location, and risk of death for undiagnosed patients.
Cybersecurity Risk with MiniMed 600 Systems Prompts Alert from FDA, Medtronic
September 20th 2022Announced on September 20, the alerts from the FDA and Medtronic notify users of a potential cybersecurity risk identified through internal testing at Medtronic that would allow unauthorized users to the pump's communication protocol, which could allow unauthorized boluses.
Benefits of Bariatric Surgery in Adolescents Endure Beyond a Decade, Study Shows
September 20th 2022An analysis of nearly 15 years of follow-up data from 97 patients who underwent bariatric surgery during adolescence provides insight into the benefits of surgery on weight loss and comorbidities among those with severe obesity.
Patient Survey Details Preferences for Newer Oral Therapies in Type 2 Diabetes
September 16th 2022An analysis of data from patient surveys provides insight into patient preferences related to oral therapies for type 2 diabetes, with blinded results indicating a preference for SGLT2 inhibitors over oral GLP-1 RA or DPP-4 inhibitors.
Tirzepatide Cuts Time to Glycemic Targets by 4-12 Weeks vs Other Diabetes Therapies
September 14th 2022An analysis of data from SURPASS-2 and -3 provides evidence demonstrating the reduction in time to achieve glycemic targets and weight loss with use of tirzepatide compared with semaglutide 1.0 mg and long-acting insulin degludec.
High Temperatures Linked to Increased Hospitalizations for People with Diabetes
September 14th 2022An analysis of data from more than 100,000 hospitalizations for hypoglycemia and hyperglycemic emergencies provides insight into the purported increase in risk for these events observed with extreme heat.
In Gestational Diabetes, Tighter Glycemic Targets Could Influence Outcomes for Mother and Child
September 11th 2022Results of the TARGET trial provide insight into the effects of tight glycemic targets versus less tight targets on maternal and perinatal outcomes among women with gestational diabetes.
FDA Updates Finerenone Label to Reflect Cardiovascular Outcomes Data
September 8th 2022On September 1, Bayer announced the US FDA had approved a label update for finerenone (Kerendia), which received initial approval in July 2021 for chronic kidney disease associated with type 2 diabetes, to include cardiovascular outcomes data from the FIGARO-DKD trial.